<?xml version="1.0" encoding="UTF-8"?>
<p>Finally, nucleic acid-based vaccines against CHIKV are under development. These vaccines have clear advantages, from ease of production, to safety, to the ability to induce both humoral and cell-mediated immunity; however many have shown a relatively low immunogenicity, requiring large doses, repeated boosters, and the use of adjuvants [
 <xref rid="pntd.0006919.ref012" ref-type="bibr">12</xref>]. One RNA-based vaccine, VAL-181388, is recruiting for a Phase 1 clinical trial (
 <xref rid="pntd.0006919.t001" ref-type="table">Table 1</xref>).
</p>
